A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies

NCT05862259 · clinicaltrials.gov ↗

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Malignant Tumor
Immunotherapy
Artificial Intelligence

Sponsor

Xinqiao Hospital of Chongqing